Medical device and MedTech insights, news, tips and more

Potrero Medical Receives FDA Breakthrough Device Designation for Accuryn AKI Predict Algorithm

September 13, 2022

monitor

Potrero Medical announced that the FDA granted Breakthrough Device Designation for their AKI Predict machine learning algorithm, for the advanced prediction of acute kidney injury (AKI) associated with intra-abdominal hypertension (IAH) in cardiac post-surgical intensive care patients.

Joe Urban, Potrero CEO stated “We celebrate the breakthrough designation, and we are excited about what this will mean for patients, providers and health systems in the future.”  Urban further commented “Continuous urine output and intra-abdominal pressure are new patient parameters that, until Accuryn, have not been available to leverage as critical data streams. Combining Accuryn technology with a predictive AKI algorithm will enhance the clinical decision support we provide at the bedside.”

To receive breakthrough designation from the FDA, there are several criteria that must be met. First, the device must provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions. Next, the device must meet one of the following: 2a) it represents breakthrough technology, 2b) no approved or cleared alternative exists, 2c) it offers significant advantages over existing approved or cleared alternatives, or 2d) device availability is in the best interest of patients.

About Potrero Medical

Potrero Medical, Inc. is a personalized platform transforming patient care through precision fluid management and analytics that offer clinical decision support by providing precise data from the kidney. Potrero Medical was founded with a mission to improve patient care and save health systems money with the latest advances in artificial intelligence and sensors. Potrero Medical is headquartered in Hayward, CA. For more information, visit potreromed.com 

See Full Press Release at the Source: Potrero Medical Receives FDA Breakthrough Device Designation for Accuryn AKI Predict Algorithm


Press Release by: Potrero Medical


Legacy MedSearch has more than 35 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 17 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.